University of Miami initiates clinical trial of XM-ONE®

The transplantation unit at Jackson Memorial Hospital and the University of
Miami, FL, USA has entered into a research project with the Allenex group
company AbSorber. The project is a pilot study evaluating the endothelial cell
cross match XM-ONE® in their Living Donor program. University of Miami will
investigate if antibodies detected by XM-ONE® will affect the outcome for the
individual patient, in pre- and post-transplant situations.
Corrected name: Dr Giselle Guerra. This news item sent first time June 7.

“Non-HLA antibodies, especially endothelial cell antibodies, play a significant
role as risk markers of acute rejection in kidney transplant recipients” says
Dr. Giselle Guerra, MD at the University of Miami and principal investigator of
the study. “However, the post-transplant risk evaluation of these antibodies
have not been studied and we are excited to have this possibility”, she
continues.

This prospective pilot study will include 138 patients and is estimated to have
an enrollment period of two years. Patients will thereafter be monitored for six
months post transplantation.

“The last years a number of researchers have published important data on the
relevance of non-HLA antibodies as well as XM-ONE® used for risk assessment in a
pre-transplant setting. An obvious next step is to investigate the presence and
importance of non-HLA antibodies post-transplantation using XM-ONE®. We are
proud that Dr. Guerra and her co-workers at Jackson Memorial Hospital approached
us to perform this important study”, says Anders Karlsson, CEO of Allenex..

For more information please contact:
Anders Karlsson, CEO Allenex AB, ph.: +4670-918 0010, e-mail:
anders.karlsson@allenex.se

Allenex AB discloses the information provided herein pursuant to the Securities
Markets Act and/or the Financial Instruments Trading Act. The information was
submitted for publication on June 8, 2012, at 10.01 CET.

Allenex is a life science-company that develop, manufacture, market and sell
products for safer transplants of organs and bone marrow on the global market.
Allenex is listed on NASDAQ OMX Stockholm Small Cap (ticker: ALNX). 54 persons
are employed in the Allenex group.